Cat. No.: HY-106328

Fluasterone

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Fluasterone is a potent G6PD inhibitor with a K_i of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.84%
CAS No.: 112859-71-9
Formule: C₁₉H₂₇FO
Masse moléculaire:290.42

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Fluasterone Chemical Structure

CAS No.: 112859-71-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Fluasterone is a potent G6PD inhibitor with a K_i of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active^[1]^[2]^[3].

IC₅₀ & Target

Ki: 0.51 μM (G6PD)^[3]

Cellular Effect

Cell Line	Type	Value	Description	References
MCF7	IC₅₀	0.5 μM Compound: 1	Inhibition of CYP1B1 in human MCF7 cells assessed as reduction in DMBA-induced CYP1B1-mediated EROD activity by EROD assay Inhibition of CYP1B1 in human MCF7 cells assessed as reduction in DMBA-induced CYP1B1-mediated EROD activity by EROD assay	[PMID: 30503941]
MCF7	IC₅₀	2.5 μM Compound: 1	Inhibition of CYP1B1 in human MCF7 cells assessed as reduction in TCDD-induced CYP1B1-mediated EROD activity by EROD assay Inhibition of CYP1B1 in human MCF7 cells assessed as reduction in TCDD-induced CYP1B1-mediated EROD activity by EROD assay	[PMID: 30503941]

In Vivo

Fluasterone (0.2% and 0.3%; in diet for 39 days) shows anti-hyperglycemic effect in diabetic mice^[2].
Fluasterone (200 μg/mouse; intradermal injection; once) suppresses the TPA-induced acute inflammatory and epidermal hyperplastic effect^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/KsJ db/db mice, diabetic model^[2]
Dosage:

0.2% and 0.3%
Administration:

In the diet for 39 days
Result:

Markedly reduced plasma glucose levels.

Chemical Information

CAS No. 112859-71-9
Appearance Solid
Masse moléculaire 290.42
Formule C₁₉H₂₇FO
Color White to off-white
SMILES

C[C@@]12[C@](C[C@@H](F)C2=O)([H])[C@@]3([H])[C@]([C@@]4(C(CCCC4)=CC3)C)([H])CC1
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Ann Med Surg (Lond)

Synergistic mechanism of Shengyang Shiyiwei Pill in enhancing bevacizumab efficacy for hepatocellular carcinoma-associated ascites. [Abstract]

2025 Nov 25;88(1):290-302. PMID: 41496997

Solvant et solubilité

In Vitro:

DMSO : 10 mg/mL (34.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4433 mL

17.2164 mL

34.4329 mL

5 mM

0.6887 mL

3.4433 mL

6.8866 mL

10 mM

0.3443 mL

1.7216 mL

3.4433 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (3.44 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (275 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Schwartz AG, et al. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. Cancer Lett. 2001 Jul 10;168(1):7-14. [Content Brief]

[2]. Schwartz AG, et al. Potential therapeutic use of dehydroepiandrosterone and structural analogs. Diabetes Technol Ther. 2001 Summer;3(2):221-4. [Content Brief]

[3]. Pashko LL, et al. Antihyperglycemic effect of dehydroepiandrosterone analogue 16 alpha-fluoro-5-androsten-17-one in diabetic mice. Diabetes. 1993 Aug;42(8):1105-8. [Content Brief]

[4]. Schwartz AG, et al. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. Cancer Lett. 2001 Jul 10;168(1):7-14.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4433 mL	17.2164 mL	34.4329 mL	86.0822 mL
	5 mM	0.6887 mL	3.4433 mL	6.8866 mL	17.2164 mL
	10 mM	0.3443 mL	1.7216 mL	3.4433 mL	8.6082 mL
	15 mM	0.2296 mL	1.1478 mL	2.2955 mL	5.7388 mL
	20 mM	0.1722 mL	0.8608 mL	1.7216 mL	4.3041 mL
	25 mM	0.1377 mL	0.6887 mL	1.3773 mL	3.4433 mL
	30 mM	0.1148 mL	0.5739 mL	1.1478 mL	2.8694 mL

Keywords

Fluasterone

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Fluasterone

Reprogramming Compound Library

Anti-diabetic Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Rare Diseases Drug Library

Human Metabolite Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Cysteine Targeted Covalent Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) Fluasterone

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Fluasterone Related Classifications

HY-106328 Related Classifications